Entrepreneurs at OHSU: you now have access to technology development resources via a new agreement with Virogenomics BioDevelopment, a 2015 spin-off of OHSU and Virogenomics, Inc. Working with universities across Oregon, biotech companies, and national institutions, Virogenomics brings together the scientific, regulatory, and funding components necessary to move technology out of the lab and into the marketplace. The idea is to help investigators find solutions to common problems such as applying for and managing STTR/SBIR grants, obtaining independent analyses of technologies and markets, and creating commercialization pipelines. The expectation is that the STTR/SBIR services will be especially helpful for OHSU entrepreneurs because it allows them to apply for funds without the complications and risk of creating a new business with an unproven technology.
Through this collaboration, both OHSU and Virogenomics BioDevelopment are working together to identify technology projects of mutual interest. OHSU researchers who are developing early-stage technologies and want to obtain funding to move forward are the ideal beneficiaries of this partnership.
Virogenomics BioDevelopment’s portfolio includes the spin out of four startup companies. One of these is OHSU spinout Artielle ImmunoTherapeutics, a privately-held, clinical-stage pharmaceutical development company. Under their management, Artielle has raised $19 million in venture financing to complete a Phase 1 clinical trial to treat multiple sclerosis.
For more information about this collaboration, please contact Andrew Watson, Ph.D., director of technology transfer, at email@example.com or 503-494-8309.